Balwinder Singh, Sagar V Parikh, Jennifer L Vande Voort, Vanessa K Pazdernik, Eric D Achtyes, Fernando S Goes, Anastasia K Yocum, Louis Nykamp, Alexis Becerra, LeAnn Smart, John F Greden, William V Bobo, Mark A Frye, Katherine E Burdick, Kelly A Ryan
This nonrandomized, multicenter, open-label clinical trial explored the impact of intravenous (IV) ketamine on cognitive function in adults (n = 74) with treatment-resistant depression (TRD). Patients received three IV ketamine infusions during the acute phase and, if remitted, four additional infusions in the continuation phase (Mayo site). Cognitive assessments using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were conducted at baseline, end of the acute phase, and end of the continuation phase (Mayo site)...
February 28, 2024: Psychiatry Research